Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Blood Test Forecasts Immunotherapy Success in Triple-Negative Breast Cancer

A groundbreaking study has emerged from leading researchers at Fudan University Shanghai Cancer Center and the Shanghai Institute for Biomedical and Pharmaceutical Technologies, illuminating a transformative pathway in the treatment of triple-negative breast cancer (TNBC). This aggressive breast cancer subtype, characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, has long defied targeted therapies, leavi…

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

A new study has identified a set of plasma proteins that can predict whether patients with triple-negative breast cancer (TNBC) will respond to immunotherapy. By analyzing blood samples from 195 TNBC patients, researchers discovered that proteins like ARG1, NOS3 and CD28 are strongly linked to treatment outcomes.